Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Emyria Ltd

EMD.AX ✓ COMPLIANTFree checks used up today ☆ Track — members

ASX · Healthcare · Biotechnology & Medical Research ·

Australia Micro Cap Analyst: N/A

Last Close

$0.03

▼ -4.00%

Market Cap $27.55M · Vol 3.64M

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$27.55M

Micro Cap

Div Yield

0.00%

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

55.56

Momentum

Beta

0.99

vs Market

52W High

$0.06

30.19% below

52W Low

$0.03

42.29% above

Volume

3.64M

Avg 1.64M

P/B

3.65

Price-to-book

ROE

N/A

Return on equity

Free Float

74.17%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Emyria Ltd (EMD.AX) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does EMD.AX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+2.13%

+26.32%

+20.00%

YTD

-18.64%

-4.00%

-31.77%

-78.02%

Financials & Valuation

TTM · Annual

Total Revenue	$2.80M
Net Income	$-4,230,540.00
Revenue Growth (YoY)	+239.28%
Gross Margin	16.31%
Operating Margin	-143.28%
Net Profit Margin	-150.84%
ROE	N/A
ROA · ROIC	-67.51% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	7.30
P/B	3.65
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	806.56M

Technical Indicators

50-Day SMA	$0.03
200-Day SMA	$0.03
RSI (14)	55.56
Beta	0.99
52-Week High	$0.06
52-Week Low	$0.03

Volume Today	3.64M
Avg Daily Volume (30D)	1.64M
Relative Volume	2.22x
Volatility (10D)	66.89
Volatility (30D)	59.74
Free Float	74.17%

Analyst Consensus

N/A

Current Price $0.03

Mean Target N/A

52W Low$0.03 52W High$0.06

Current

Target

$0.03 $0.06

Current Analyst target

· 0 analysts

Identifiers

ExchangeASX

FIGIBBG00R41CRB8

ISINAU0000073645

CountryAustralia

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LONN.S Lonza Group AG +0.59% ONC BeOne Medicines AG +4.23% 068270.KS Celltrion, Inc. +1.11% MEDP Medpace Holdings, Inc. +1.94% ABVX Abivax SA -1.51%

Company Profile

Emyria Limited is an Australia-based early-stage drug development company. The Company is focused on delivering and developing treatments for mental health and select neurological conditions, guided by real-world data collected with patients across its wholly owned clinical service subsidiaries. Its pipeline comprises MDMA analogue drug development and commercialization of novel serotonin-releasing agents. Its Emyria Healthcare provides evidence-based treatment for patients not finding relief from conventional care, while also helping evaluate emerging new therapies like assisted therapy for post-traumatic stress disorder (PTSD) and assisted therapy for treatment-resistant depression. Its Emyria Data is a robust and ethically sourced real-world data gathered with patients and used to improve its therapy and drug development programs. Its Emyria’s Pipeline includes new psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases.